3,708 Shares in Axsome Therapeutics, Inc. $AXSM Purchased by Two Sigma Securities LLC

Two Sigma Securities LLC bought a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 3,708 shares of the company’s stock, valued at approximately $908,000.

Several other hedge funds also recently made changes to their positions in the stock. Kemnay Advisory Services Inc. purchased a new position in Axsome Therapeutics during the 4th quarter valued at about $31,000. Hollencrest Capital Management raised its holdings in shares of Axsome Therapeutics by 400.0% in the 1st quarter. Hollencrest Capital Management now owns 200 shares of the company’s stock valued at $34,000 after acquiring an additional 160 shares in the last quarter. Ameriflex Group Inc. bought a new stake in shares of Axsome Therapeutics during the 4th quarter valued at about $37,000. ABS Investment Management LLC purchased a new position in shares of Axsome Therapeutics during the second quarter worth about $171,339,000. Finally, Silvant Capital Management LLC bought a new position in shares of Axsome Therapeutics in the second quarter worth approximately $66,000. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have commented on AXSM. BMO Capital Markets began coverage on shares of Axsome Therapeutics in a research note on Monday, July 20th. They issued an “outperform” rating and a $310.00 price target for the company. UBS Group restated a “buy” rating on shares of Axsome Therapeutics in a research report on Monday, August 24th. HC Wainwright reaffirmed a “buy” rating and set a $290.00 price objective on shares of Axsome Therapeutics in a report on Monday. Needham & Company LLC lifted their price objective on shares of Axsome Therapeutics from $267.00 to $268.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Finally, Wells Fargo & Company upped their target price on shares of Axsome Therapeutics from $255.00 to $256.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 11th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Axsome Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $267.60.

Insider Activity

In other Axsome Therapeutics news, Director Roger Jeffs sold 286 shares of the firm’s stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $246.18, for a total value of $70,407.48. Following the completion of the sale, the director directly owned 58,653 shares in the company, valued at $14,439,195.54. This trade represents a 0.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Mark Coleman sold 643 shares of the firm’s stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $249.00, for a total transaction of $160,107.00. Following the completion of the sale, the director owned 30,389 shares of the company’s stock, valued at $7,566,861. This trade represents a 2.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 183,229 shares of company stock worth $42,666,176. 20.60% of the stock is owned by company insiders.

Axsome Therapeutics Stock Down 0.3%

NASDAQ AXSM opened at $198.52 on Tuesday. Axsome Therapeutics, Inc. has a 1 year low of $112.90 and a 1 year high of $260.19. The stock has a market capitalization of $10.40 billion, a PE ratio of -52.94 and a beta of 0.65. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.43 and a quick ratio of 1.34. The business’s 50-day moving average is $226.44 and its 200 day moving average is $206.99.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.10). Axsome Therapeutics had a negative net margin of 24.68% and a negative return on equity of 265.55%. The company had revenue of $218.38 million for the quarter, compared to analysts’ expectations of $221.11 million. Sell-side analysts forecast that Axsome Therapeutics, Inc. will post -2.8 earnings per share for the current year.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.